中日创新药物市场准入政策环境比较及对我国的启示  

Comparison of Sino-Japanese innovative drug market access policy environment and enlightenment to China

作　　者：王恩楠 陈怡[1] 褚淑贞[1] 

机构地区：[1]中国药科大学国际医药商学院,南京211198

出　　处：《中国药科大学学报》2017年第6期745-750,共6页Journal of China Pharmaceutical University

基　　金：国家社会科学基金资助项目(No.15ZDB167)~~

摘　　要：从知识产权、药品定价、医疗保障和招标采购等创新药物市场准入基本环节入手,分类总结我国创新药物市场准入政策现状及存在问题。在分析日本创新药物市场准入政策的基础上,通过对比两国创新药物市场准入政策差异,从知识产权、药品定价、医疗保障和招标采购等4个方面提出激励我国创新药物上市准入的建议措施。This paper summarizes the current situation and existing problems of China＇s innovative drug market access policy from the basic aspects of innovative drug market access,such as intellectual property rights,drug pricing,medical insurance and bidding procurement.Based on the comprehensive analysis of Japan＇ s innovative drug market access policy,through the comprehensive comparison of the two countries innovative drug market access policy differences,the paper put forward the practical measures to encourage the listing of innovative drugs in China,from the intellectual property rights,drug pricing,medical security and tender procurement in four areas.

关 键 词：创新药物 市场准入 政策比较 中国 日本 

分 类 号：R95[医药卫生—药学]